Skip to main content
Clinical Trials/NCT03845374
NCT03845374
Completed
Not Applicable

Prospective, Randomized Multi-Center Study of Using the Hyper-CL™ Lens in Subjects Suffering From Bacterial Keratitis

Eye-yon Medical2 sites in 1 country12 target enrollmentMarch 13, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bacterial Keratitis
Sponsor
Eye-yon Medical
Enrollment
12
Locations
2
Primary Endpoint
Change in Bacterial Keratitis severity score
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

This study is a prospective, randomized, open-label, two arms, clinical study aim to evaluate the efficacy and safety of treatment with Hyper-CL™ lens + Antibiotics compared with treatment with Antibiotics only, in subjects with Bacterial keratitis.

The design of the Hyper-CL™ lens increases contact time of the antibiotics on the cornea enabling increased bioavailability of the active drug.

Detailed Description

The Hyper-CL™ Therapeutic soft contact lenses for short-term wear (up to 7 days) are indicated for therapeutic use to promote corneal healing and relieve corneal pain by protecting the cornea during the treatment of acute or chronic pathologies, such as corneal edema, corneal erosions, entropion, bullous keratopathy, and corneal dystrophies as well as post-surgical conditions resulting from cataract extraction and corneal surgery.

Registry
clinicaltrials.gov
Start Date
March 13, 2019
End Date
January 11, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Eye-yon Medical
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subject is 18-86 years old
  • Subject with Bacterial keratitis in one eye only
  • Subject with Bacterial Keratitis of at least grade 2 score in Average length of infiltration and in Average length of epithelial defect (1mm or above)
  • Best-corrected visual acuity of 6/60 or better in the uninvolved eye
  • No prior antibiotic treatment for current Bacterial Keratitis
  • Subject understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed

Exclusion Criteria

  • Perforation or imminent perforation of cornea
  • Subject with glaucoma shunts (e.g. Ahmed valve) and or bleb
  • Sign of inflammation in both eyes
  • Severe itching suggesting viral infection or allergy reaction
  • Subepithelial infiltrate suggesting viral infection
  • Dendrite like ulcer or suspecting of Herpes keratitis
  • Previous penetrating keratoplasty
  • No light perception in the affected eye
  • Other active ocular infection
  • Any infiltration suggesting other than bacterial infection e.g. parasite, fungal

Outcomes

Primary Outcomes

Change in Bacterial Keratitis severity score

Time Frame: From date of randomization up to 14 days

Will be measured by Bacterial keratitis severity score (0-5). A low score is considered an improvement, a high score is considered worsening.

Study Sites (2)

Loading locations...

Similar Trials